A case report of orbital inflammatory syndrome secondary to ipilimumab

Amanda D. Henderson, Dilip Abraham Thomas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell-mediated immune response. Ipilimumab is approved by the US Food and Drug Administration for the treatment of advanced melanoma. However, its use frequently has been associated with immune-related side effects, which can be explained by its mechanism of action. More common adverse effects include dermatitis, colitis, hepatitis, and endocrinopathies, but many less common immune-related adverse effects that involve various tissues and organ systems have been reported with more widespread use of ipilimumab since its approval in 2011. A case of bilateral orbital inflammatory syndrome secondary to ipilimumab, in a patient undergoing adjuvant treatment for metastatic melanoma, is reported.

Original languageEnglish (US)
Pages (from-to)e68-e70
JournalOphthalmic Plastic and Reconstructive Surgery
Volume31
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Melanoma
CTLA-4 Antigen
Dermatitis
United States Food and Drug Administration
Colitis
Hepatitis
Monoclonal Antibodies
T-Lymphocytes
ipilimumab
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

A case report of orbital inflammatory syndrome secondary to ipilimumab. / Henderson, Amanda D.; Thomas, Dilip Abraham.

In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 31, No. 3, 01.01.2015, p. e68-e70.

Research output: Contribution to journalArticle

@article{7ebdb746ee094c2d92984fc4590e68eb,
title = "A case report of orbital inflammatory syndrome secondary to ipilimumab",
abstract = "Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell-mediated immune response. Ipilimumab is approved by the US Food and Drug Administration for the treatment of advanced melanoma. However, its use frequently has been associated with immune-related side effects, which can be explained by its mechanism of action. More common adverse effects include dermatitis, colitis, hepatitis, and endocrinopathies, but many less common immune-related adverse effects that involve various tissues and organ systems have been reported with more widespread use of ipilimumab since its approval in 2011. A case of bilateral orbital inflammatory syndrome secondary to ipilimumab, in a patient undergoing adjuvant treatment for metastatic melanoma, is reported.",
author = "Henderson, {Amanda D.} and Thomas, {Dilip Abraham}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/IOP.0000000000000081",
language = "English (US)",
volume = "31",
pages = "e68--e70",
journal = "Ophthalmic Plastic and Reconstructive Surgery",
issn = "0740-9303",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A case report of orbital inflammatory syndrome secondary to ipilimumab

AU - Henderson, Amanda D.

AU - Thomas, Dilip Abraham

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell-mediated immune response. Ipilimumab is approved by the US Food and Drug Administration for the treatment of advanced melanoma. However, its use frequently has been associated with immune-related side effects, which can be explained by its mechanism of action. More common adverse effects include dermatitis, colitis, hepatitis, and endocrinopathies, but many less common immune-related adverse effects that involve various tissues and organ systems have been reported with more widespread use of ipilimumab since its approval in 2011. A case of bilateral orbital inflammatory syndrome secondary to ipilimumab, in a patient undergoing adjuvant treatment for metastatic melanoma, is reported.

AB - Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell-mediated immune response. Ipilimumab is approved by the US Food and Drug Administration for the treatment of advanced melanoma. However, its use frequently has been associated with immune-related side effects, which can be explained by its mechanism of action. More common adverse effects include dermatitis, colitis, hepatitis, and endocrinopathies, but many less common immune-related adverse effects that involve various tissues and organ systems have been reported with more widespread use of ipilimumab since its approval in 2011. A case of bilateral orbital inflammatory syndrome secondary to ipilimumab, in a patient undergoing adjuvant treatment for metastatic melanoma, is reported.

UR - http://www.scopus.com/inward/record.url?scp=84899782496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899782496&partnerID=8YFLogxK

U2 - 10.1097/IOP.0000000000000081

DO - 10.1097/IOP.0000000000000081

M3 - Article

C2 - 24814274

AN - SCOPUS:84899782496

VL - 31

SP - e68-e70

JO - Ophthalmic Plastic and Reconstructive Surgery

JF - Ophthalmic Plastic and Reconstructive Surgery

SN - 0740-9303

IS - 3

ER -